- Home
- GO vs GLPG Comparison
GO vs GLPG Comparison
Compare GO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GO
- GLPG
- Stock Information
- Founded
- GO 1946
- GLPG 1999
- Country
- GO United States
- GLPG Belgium
- Employees
- GO N/A
- GLPG N/A
- Industry
- GO Food Chains
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- GO Consumer Staples
- GLPG Health Care
- Exchange
- GO Nasdaq
- GLPG Nasdaq
- Market Cap
- GO 1.6B
- GLPG 1.8B
- IPO Year
- GO 2019
- GLPG 2005
- Fundamental
- Price
- GO $13.54
- GLPG $24.60
- Analyst Decision
- GO Hold
- GLPG Sell
- Analyst Count
- GO 12
- GLPG 5
- Target Price
- GO $16.08
- GLPG $26.75
- AVG Volume (30 Days)
- GO 2.6M
- GLPG 159.8K
- Earning Date
- GO 05-06-2025
- GLPG 04-23-2025
- Dividend Yield
- GO N/A
- GLPG N/A
- EPS Growth
- GO N/A
- GLPG N/A
- EPS
- GO 0.40
- GLPG 1.16
- Revenue
- GO $4,371,501,000.00
- GLPG $285,380,474.00
- Revenue This Year
- GO $11.52
- GLPG $0.08
- Revenue Next Year
- GO $6.44
- GLPG $0.23
- P/E Ratio
- GO $33.14
- GLPG $21.87
- Revenue Growth
- GO 10.13
- GLPG 14.99
- 52 Week Low
- GO $10.26
- GLPG $22.36
- 52 Week High
- GO $28.98
- GLPG $32.57
- Technical
- Relative Strength Index (RSI)
- GO 52.40
- GLPG 46.62
- Support Level
- GO $12.73
- GLPG $25.07
- Resistance Level
- GO $12.97
- GLPG $25.72
- Average True Range (ATR)
- GO 0.60
- GLPG 0.50
- MACD
- GO 0.25
- GLPG -0.12
- Stochastic Oscillator
- GO 96.23
- GLPG 20.10
About GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. Its flexible buying model allows them to offer quality, name-brand opportunistic products at prices generally 40% to 70% below those of conventional retailers. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.